Intelligence · Clinical Development
Pipeline search results
Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
811095
BRIGHT MINDS BIOSCIENCES INC.
Amphetamine Dependence
1 trial -
ALXN1720 Placebo Product, Gefurulimab
Alexion Europe SAS
Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)
1 trial -
ALXN1850 placebo product, ALXN1850
Alexion Europe SAS
Hypophosphatasia
1 trial -
ALXN1850, ALXN1850 placebo product
Alexion Europe SAS
hypophosphatasia
1 trial -
AM-PHN-004
Amneal Pharma Europe Ltd
Uncomplicated Urinary Tract Infections
1 trial -
AMG 133, Placebo for Maridebart Cafraglutide
Amgen
Chronic Weight Management
1 trial -
ARO-APOC3 PFS, Plozasiran Injection Placebo
Arrowhead Pharmaceuticals Ireland Limited
Severe hypertriglyceridemia (SHTG)
1 trial -
ARO-APOC3 PFS, Plozasiran Injection Placebo
Arrowhead Pharmaceuticals Ireland Limited
Hypertriglyceridemia
1 trial -
AVP-786 matching placebo, AVP-786
Otsuka Beijing Research Institute
Agitation in Patients With Dementia of the Alzheimer's Type
1 trial -
AZD0780 Placebo, AZD0780
AstraZeneca AB
Heterozygous familial hypercholesterolaemia
1 trial -
AZD0780, AZD0780 Placebo
AstraZeneca AB
Hyperlipidemia, Atherosclerotic cardiovascular disease
1 trial -
AZD0780, AZD0780 placebo
AstraZeneca AB
Atherosclerotic Cardiovascular Disease
1 trial -
Abrocitinib Placebo, Abrocitinib
Pfizer Australia Pty Ltd
Moderate-to-Severe Atopic Dermatitis
1 trial -
Afinitor 5 mg tablets, PLACEBO
Ningbo Cancer Hospital
Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free
1 trial -
Anakinra 100mg and Placebo Depo-Medrone
United Therapeutics Europe Ltd
Gout
1 trial -
Anifrolumab, Anifrolumab Placebo
AstraZeneca AB
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria
1 trial -
Atogepant, Placebo for Atogepant
AbbVie Deutschland GmbH & Co. KG
Menstrual Migraine
1 trial -
Atogepant, Placebo for Atogepant
AbbVie Deutschland GmbH & Co. KG
Chronic Migraine
1 trial -
Atogepant, Placebo for atogepant tablets 60mg
AbbVie Deutschland GmbH & Co. KG
Migraine
1 trial -
Azilsartan medoxomil/placebo
Takeda
Essential Hypertension
1 trial -
BAY 3427080, BAY 3427080 60 mg capsules placebo
Bayer AG
Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer
1 trial -
BI 764198, Placebo matching BI 764198
Boehringer Ingelheim
Focal segmental glomerulosclerosis
1 trial -
Baxdrostat, Baxdrostat Placebo
AstraZeneca AB
Resistant hypertension (rHTN) defined as blood pressure that remains higher than goal levels despite the use of at least 3 anti hypertensive drugs of different classes at maximum tolerated dose, including a diuretic.
1 trial -
Bexotegrast, Placebo matching PLN-74809
PLIANT THERAPEUTICS, INC.
Idiopathic pulmonary fibrosis (IPF)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.